| Literature DB >> 25741070 |
Lorena Pozzo1, George Coura Filho2, João Alberto Osso Júnior3, Peterson Lima Squair4.
Abstract
OBJECTIVE: To investigate the outpatient access to nuclear medicine procedures by means of the Brazilian Unified Health System (SUS), analyzing the correspondence between data provided by this system and those from Comissão Nacional de Energia Nuclear (CNEN) (National Commission of Nuclear Energy).Entities:
Keywords: Gamma camera; Nuclear medicine; SUS
Year: 2014 PMID: 25741070 PMCID: PMC4337145 DOI: 10.1590/0100-3984.2013.1906
Source DB: PubMed Journal: Radiol Bras ISSN: 0100-3984
Products made by IPEN/CNEN-SP, their applications and coverage by SUS*.
| Name of the group / product | Application | SUS |
|---|---|---|
| Technetium generator-99mTc | Labeling of lyophilized kits and tests; activities 250 mCi, 500 mCi, 750 mCi, 1000 mCi, 1250 mCi, 1500 mCi and 2000 mCi | Yes |
| Sodium iodide-131I | Thyroid function study | Yes |
| Sodium iodide-131I capsule | Treatment of thyroid cancer and hyperthyroidism | Yes |
| Sodium iodide-123I | Thyroid function study | Yes |
| Thallium chloride-201Tl | Stress and rest cardiac imaging to assess cardiac muscle injury extent. | Yes |
| Sodium chromate-51Cr | Labeling of erythrocytes. Splenic gammagraphy | Yes |
| Gallium citrate-67Ga | Localization of tumors in soft tissue and inflammatory lesions | Yes |
| 131I-MIBG | Pheochromocytomas and neuroblastomas scintigraphy | Yes |
| 123I-MIBG | Scintigraphy of suprarenal tumors and pheochromocytomas-neuroblastomas | No |
| 131I-SAH | Determination of plasma and blood volume | No |
| Hippuran-131I | Renal function study | Yes |
| Lipiodol-131I | Hepatomas therapy | No |
| EDTA-51Cr | Glomerular filtration rate determination | Yes |
| Human serum albumin-51Cr | Gastrointestinal protein loss study | No |
| EDTMP-153Sm | Relief of pain caused by bone metastases. Therapeutic dose from 70 to 100 mCi | Yes |
| Hydroxypatite-153Sm | Rheumatoid arthritis treatment | No |
| FDG-18F | Diagnosis of cardiac function, breast cancer, lymphoma and lung cancer | No |
| 111In DTPA octreotate | Study of neuroendocrine tumors and other types of cancer such as lymphoma, kidney, lung, brain and breast | No |
| Hydroxypatite-90Y | Treatment of rheumatoid arthritis | No |
| 177Lu DOTA octreotate | Treatment of neuroendocrine tumors and other types of cancer such as lymphoma, kidney, lung, brain and breast | No |
| GHA | Renal and brain scintigraphy | No |
| HSA | Blood flow studies and placental scintigraphy | No |
| Dextran 500 | Lymphatic system study | Yes |
| Dextran 70 | Lymphatic system study | Yes |
| Disida | Hepatobiliary scintigraphy | Yes |
| DMSA | Renal scintigraphy | Yes |
| DTPA | Renal and brain scintigraphy | Yes |
| EC | Renal function study | No |
| ECD | Cerebral perfusion study | No |
| Colloidal tin | Hepatosplenic scintigraphy | Yes |
| Sodium phytate | Hepatic scintigraphy | Yes |
| MAA | Lung scintigraphy | Yes |
| MDP | Bone scintigraphy | Yes |
| Sodium pyrophosphate | Bone scintigraphy, diagnosis of acute myocardial infarction, | Yes |
| SAH | Cardiac blood pooling and ventriculography | Yes |
| MIBI | Evaluation of myocardial perfusion and detection of breast and parathyroid tumors | Yes |
Modified from https://www.ipen.br/conteudo/upload/201009101032310.ipen_produtos_servicos_082010.doc .
Figure 1Regional distribution of the seven nuclear medicine procedures most performed by SUS and procedures/1,000 inhabitants ratio
Figure 2National outpatient procedures production by SUS per administrative instance in 2012
Outpatient procedures production at SUS per region and per administrative level in 2012.
| Region | Federal | State | Municipality | Private |
|---|---|---|---|---|
| North | 0.0% | 5.4% | 0.0% | 94.6% |
| Northeast | 3.1% | 6.1% | 0.0% | 90.8% |
| Southeast | 2.9% | 18.5% | 0.6% | 78.0% |
| South | 9.8% | 3.0% | 1.2% | 85.9% |
| Mid-west | 8.7% | 12.8% | 0.0% | 78.5% |
Outpatient procedures production at SUS per region and per type of service in 2012.
| Region | For profit private services Individual/Legal entity | For profit private service under SIMPLES regime | Private non-profit service | Philantropic service withvalid CNES |
|---|---|---|---|---|
| North | 77.4% | 0.0% | 22.6% | 0.0% |
| Northeast | 54.2% | 0.6% | 26.0% | 19.2% |
| Southeast | 25.1% | 0.6% | 42.1% | 32.2% |
| South | 59.6% | 0.5% | 19.0% | 20.8% |
| Mid-west | 93.8% | 0.0% | 2.1% | 4.2% |
Figure 3Contribution of the different types of service providers to specialized outpatient in vivo nuclear medicine service in the period between 2008 and 2012.
Services that provide nuclear medicine procedures with in-house or outsourced resources
| In-house services | Outsourced services | ||
|---|---|---|---|
| Private services | 615 | 433 (70.4%) | 177 (28.8%) |
| Public services | 161 | 43 (26.7%) | 118 (73.3%) |
| Total | 776 | 476 | 295 |
In-house nuclear medicine services and services authorized by CNEN per State and region
| State and region | Services authorizedby CNEN | In-house nuclear medicine services |
|---|---|---|
| Rondônia | 2 | 2 |
| Acre | 2 | 1 |
| Amazonas | 5 | 3 |
| Roraima | 1 | 1 |
| Pará | 11 | 12 |
| Amapá | 2 | 1 |
| Tocantins | 1 | 3 |
|
|
|
|
| Maranhão | 6 | 6 |
| Piauí | 4 | 4 |
| Ceará | 7 | 7 |
| Rio Grande do Norte | 4 | 10 |
| Paraíba | 3 | 8 |
| Pernambuco | 11 | 12 |
| Alagoas | 6 | 10 |
| Sergipe | 3 | 5 |
| Bahia | 12 | 20 |
|
|
|
|
| Minas Gerais | 52 | 64 |
| Espírito Santo | 13 | 8 |
| Rio de Janeiro | 42 | 52 |
| São Paulo | 120 | 122 |
|
|
|
|
| Paraná | 28 | 37 |
| Santa Catarina | 9 | 26 |
| Rio Grande do Sul | 32 | 46 |
|
|
|
|
| Mato Grosso do Sul | 5 | 5 |
| Mato Grosso | 5 | 3 |
| Goiás | 9 | 14 |
| Distrito Federal | 17 | 9 |
|
|
|
|